Focal Therapy

Our Publications on Focal Therapy

Valerio, M, Stricker PD, H. U. Ahmed, L. Dickinson, L. Ponsky, Shnier R, C. Allen, and M. Emberton. 2014. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer Prostatic Dis, 17: 343 https://doi.org/10.1038/pcan.2014.33

Ting F, M. Tran, M. Böhm, Siriwardana A, van Leeuwen PJ, Haynes AM, Delprado W, Shnier R, and Stricker PD. 2015. Focal irreversible electroporation for prostate cancer: functional outcomes and short-term oncological control. Prostate Cancer And Prostatic Diseases, 19: 46. https://doi.org/10.1038/pcan.2015.47

Ting F, van Leeuwen PJ, and Stricker PD. 2016. Step-by-Step Technique for Irreversible Electroporation of Focal Prostate Cancer: An Instructional Video Guide. J Vasc Interv Radiol, 27: 568. https://doi.org/10.1016/j.jvir.2016.01.003

Scheltema M.J, van den Bos W, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, Bohm M, Haynes AM, Shnier R, Delprado W, and Stricker PD. 2017. Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer. BJU Int, 120 Suppl 3: 51-58. https://doi.org/10.1111/bju.13991

Scheltema MJ, Chang JI, Bohm M, van den Bos W, A. Blazevski, Gielchinsky I, Kalsbeek AMF, van Leeuwen PJ, Nguyen TV T. M. de Reijke, Siriwardana AR, Thompson JE, J. J. de la Rosette, and Stricker PD. 2018. Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. World J Urol. https://doi.org/10.1007/s00345-018-2281-z

Van den Bos W, Scheltema MJ, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, Bohm M, Haynes AM, Shnier R, Delprado W, and Stricker PD. 2018. Focal irreversible electroporation as primary treatment for localized prostate cancer. BJU Int, 121: 716-24. https://doi.org/10.1111/bju.13983

Scheltema MJ, Chang JI, van den Bos W, Gielchinsky I, Nguyen TV T. M. Reijke, Siriwardana AR, Bohm M, J. J. de la Rosette, and Stricker PD. 2018. Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments. Diagn Interv Radiol, 24: 268-75. https://doi.org/10.5152/dir.2018.17374

Scheltema M.J, T. J. O'Brien, van den Bos W, D. M. de Bruin, R. V. Davalos, C. W. M. van den Geld, M. P. Laguna, R. E. Neal, 2nd, I. M. Varkarakis, A. Skolarikos, Stricker PD, T. M. de Reijke, C. B. Arena and J. de la Rosette (2019). umerical simulation modeling of the irreversible electroporation treatment zone for focal therapy of prostate cancer, correlation with whole-mount pathology and T2-weighted MRI sequences. Ther Adv Urol 11: 1756287219852305. https://doi.org/10.1177/1756287219852305

Blazevski, A, Scheltema MJ, A. Amin, Thompson JE, N. Lawrentschuk and Stricker PD (2019). rreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. BJU Int. https://doi.org/10.1111/bju.14951

Blazevski A, Scheltema MJ, Yuen B Masand N, Nguyen TV W.Delprado, Shnier R, A. Haynes, Cusick T, Thompson J, Stricker P. Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort. Eur Urol. Oncol(2019). https://doi.org/10.1016/j.euo.2019.04.008

Blazevski, A, Scheltema MJ, A. Amin, Thompson JE, N. Lawrentschuk and Stricker PD (2020). Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. BJU Int 125(3): 369-378. https://doi.org/10.1111/bju.14951

Blazevski A, Amin A, Scheltema MJ, Balakrishnan A, Haynes AM, Barreto D, Cusick T, Thompson J, Stricker PD. Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE). World J Urol. 2021 Apr;39(4):1107-1114. https://doi.org/10.1007/s00345-020-03275-z  Epub 2020 Jun 2.

Cussenot O, Stricker PD. Irreversible electroporation for patients with localised prostate cancer: Expert opinion on this versatile therapeutic approach. EMJ Urol. 2021 Aug:9[1]:56-62. https://www.emjreviews.com/urology/article/irreversible-electroporation-for-patients-with-localised-prostate-cancer-expert-opinion-on-this-versatile-therapeutic-approach-j180121

Blazevski A, Gondoputro W, Scheltema MJ, Amin A, Geboers B, Barreto D, Haynes AM, Shnier R, Delprado W, Agrawal S, Thompson JE, Stricker PD. Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes. BMC Urol. 2022 Mar 2;22(1):28. https://doi.org/10.1186/s12894-022-00978-w.

Geboers B, Gondoputro W, Thompson JE, Reesink DJ, van Riel LAMJG, Zhang D, Blazevski A, Doan P, Agrawal S, Matthews J, Haynes AM, Liu Z, Delprado W, Shnier R, de Reijke TM, Lawrentschuk N, Stijns PEF, Yaxley JW, Scheltema MJ, Stricker PD. Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Irreversible Electroporation-A Multicenter Validation Study. Eur Urol Focus. 2022 May 13:S2405-4569(22)00106-7. https://doi.org/10.1016/j.euf.2022.04.010. Epub ahead of print.

van Riel LAMJG, Geboers B, Kabaktepe E, Blazevski A, Reesink DJ, Stijns P, Stricker PD, Casanova J, Dominguez-Escrig JL, de Reijke TM, Scheltema MJ, Oddens JR. Outcomes of salvage radical prostatectomy after initial irreversible electroporation treatment for recurrent prostate cancer. BJU Int. 2022 Apr 27. https://doi.org/10.1111/bju.15759. Epub ahead of print.

Ong S, Chen K, Grummet J, Yaxley J, Scheltema MJ, Stricker P, Tay KJ, Lawrentschuk N. Guidelines of guidelines: focal therapy for prostate cancer, is it time for consensus? BJU Int. 2022 Sep 9. https://doi.org/10.1111/bju.15883. Epub ahead of print.

Scheltema M.J, Geboers, B, Blazevski, A, Doan, P, Katelaris, A, Agrawal, S, Barreto, D, Shnier, R, Delprado, W, Thompson, J. E, & Stricker, P. D. (2022). Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer. BJU international, 10.1111/bju.15946. Advance online publication. https://doi.org/10.1111/bju.15946

Blazevski, A, Geboers, B, Scheltema M.J, Gondoputro, W, Doan, P, Katelaris, A, Agrawal, S, Baretto, D, Matthews, J, Haynes, A. M, Delprado, W, Shnier, R, Van den Bos W, Thompson, J. E, Lawrentschuk, N, & Stricker, P. D. (2022). Salvage irreversible electroporation for radio-recurrent prostate cancer - the prospective FIRE trial. BJU international, 10.1111/bju.15947. Advance online publication. https://doi.org/10.1111/bju.15947

Geboers, B, Scheltema M.J, Blazevski, A, Katelaris, A, Doan, P, Ali, I, Agrawal, S, Barreto, D, Matthews, J, Haynes, A. M, Delprado, W, Shnier, R, Thompson, J. E, & Stricker, P. D. (2023). Median 4-year outcomes of salvage irreversible electroporation for localized radio-recurrent prostate cancer. BJU international, 10.1111/bju.15948. Advance online publication. https://doi.org/10.1111/bju.15948

Emberton M, Reijke T;, Stricker P, Miñana, Bianco F, Dominguez Escrig J, Lantz A, Sanchez-Salas R. Revisiting Delphi to create a basis for the future of focal therapy for prostate cancer. Urology Journal URL-D-23-00730

Lantz A, Nordlund P, Falagario U, Jäderling F, Özbek O, Clements M, Discacciati A, Grönberg H, Eklund M, Stricker P, Emberton M, Aly M, Nordström T. Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate Cancer. Eur Urol Open Sci. 2023 Apr 8;51:89-94. https://doi.org/10.1016/j.euros.2023.03.003 . PMID: 37091033; PMCID: PMC10114162.

Deivasigamani S, Kotamarti S, Rastinehad AR, et al. Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement. Eur Urol. 2023;84(6):547-560. https://doi.org/10.1016/j.eururo.2023.06.013. Epub ahead of print. PMID: 37419773.

Scheltema MJ, Katelaris A, Stricker PD. Salvage irreversible electroporation for radio-recurrent prostate cancer. Nat Rev Urol. 2023 Mar 1. https://doi.org/10.1038/s41585-023-00750-1 . Epub ahead of print. PMID: 36859611.

Rodríguez-Sánchez L, Emberton M, de Reijke T, Stricker P, Miñana B, Bianco F, Escrig JLD, Lantz A, Sanchez-Salas R. Revisiting Delphi to Create a Basis for the Future of Focal Therapy for Prostate Cancer. World J Mens Health. 2023 Oct 16. DOI: 10.5534/wjmh.230160. Epub ahead of print. PMID: 37853538.

Zhang K, Stricker P, Löhr M, Stehling M, Suberville M, Cussenot O, Lunelli L, Ng CF, Teoh J, Laguna P, de la Rosette J. A multi-center international study to evaluate the safety, functional and oncological outcomes of irreversible electroporation for the ablation of prostate cancer.  Prostate cancer and prostatic diseases. 2024 Jan 9. https://doi.org/10.1038/s41391-023-00783-y”. Epub ahead of print. PMID: 38195916.

Geboers B, Meijer D, Counter W, et al. Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy. BJU Int. 2024;133 Suppl 4:14-22. https://doi:10.1111/bju.16207

Williams ISC, Katelaris A, Geboers B, Doan P, Delprado W, Scheltema MJ, Stricker P. Transrectal Ultrasound as Real-Time Confirmation of Adequate Needle Positioning During Irreversible Electroporation in Focal Therapy of Prostate Cancer. Videourology, 37, pp. 1 - 2 https://doi.org/10.1089/vid.2023.0046

Geboers, B., Scheltema, M. J., Jung, J., Bakker, J., Timmer, F. E. F., Cerutti, X., Katelaris, A., Doan, P., Gondoputro, W., Blazevski, A., Agrawal, S., Matthews, J., Haynes, A. M., Robertson, T., Thompson, J. E., Meijerink, M. R., Clark, S. J., de Gruijl, T. D., & Stricker, P. D. (2024). Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti-tumour T-cell activation - IRE-IMMUNO study. BJU international https://doi.org/10.1111/bju.16496

Storino Ramacciotti, L., Abreu, A. L., Crouzet, S., Macek, P., Miles, B. J., Horuz, R., Nunes-Carneiro, D., Stricker, P., Scionti, S., & Laguna, M. P. (2024). Salvage treatments after focal therapy for prostate cancer - a comprehensive review. Prostate cancer and prostatic diseases https://doi.org/10.1038/s41391-024-00875-3

Presentations

Jung J. February 2024. Irreversible electroporation of intermediate risk prostate cancer mitigates immune suppression and induces systemic antitumor T cell activation
ASANZ Meeting Adelaide

Geboers B. June 2024. Irreversible Electroporation - Cytoreduction and Immunomodulation in Oncology
PhD Dissertation Vrije University Amsterdam, the Netherlands

Geboers B. January 2023. Rising Star Session: Additional Diagnostic Accuracy of PSMA-PET to select prostate cancer patients for hemi-ablative focal therapy
SVHA research symposium, Sydney, Australia

Geboers B. July 2022. Diagnostic Accuracy of Multiparametric MRI to detect residual prostate cancer following IRE
EAU, Amsterdam, the Netherlands